Dosing & Uses
Dosage Forms & Strengths
Malignant Pleural Effusion
Indicated as a sclerosing agent to decrease malignant pleural effusion recurrence in symptomatic patients
Administered intrapleurally via chest tube after adequate drainage of the effusion
Aerosol : 4-8 g (1-2 canisters); deliver by manually pressing actuator button; distal end of the delivery tube should be pointed in several different directions, while short bursts are administered to distribute talc powder equally and extensively on all visceral and parietal pleural surfaces
Powder: 5 g as single dose dispersed in sodium chloride injection 50 to 100 mL; doses range from 2 to 10.5 g shown to be effective
Safety and efficacy not established
Frequency Not Defined
Difficult to distinguish adverse effects of talc from adverse effects of procedures associated with talc administration
Unilateral pulmonary edema
Adverse reactions due to the delivery procedure and chest tube may include pain, infection at the site of thoracostomy or thoracoscopy, localized bleeding, and subcutaneous emphysema
May preclude subsequent diagnostic procedures of the pleura on the treated side, in including ipsilateral lung resective surgery and pneumonectomy for transplantation purposes
No known antineoplastic activity and should not be used alone for potentially curable malignancies where systemic therapy would before appropriate; does not exhibit antineplastic therapy
May cause pulmonary complication (eg, acute pneumonitis, ARDS)
Keep Sclerosol (aerosol) away from any heat source that could cause it to explode
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Not studied
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Induces inflammatory reaction; this reaction promotes adherence of the visceral to the parietal pleura, thereby obliterating the pleural space and preventing reaccumulation of pleural fluid
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.